TOBI (tobramycin) ( DrugBank: Tobramycin )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 1 |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01953367 (ClinicalTrials.gov) | September 2013 | 4/9/2013 | Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects | Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects | Cystic Fibrosis | Drug: Vantobra (tobramycin);Drug: TOBI (tobramycin) | Pari Pharma GmbH | NULL | Completed | 18 Years | 50 Years | Both | 72 | Phase 1 | Germany |